nach oben

Current Diabetes Reports

Erschienen in:

01.08.2014 | Microvascular Complications—Retinopathy (JK Sun, Section Editor)

Anti-VEGF Therapy for Diabetic Macular Edema

verfasst von: Michael W. Stewart

Erschienen in: Current Diabetes Reports | Ausgabe 8/2014

Einloggen, um Zugang zu erhalten

Abstract

Vascular endothelial growth factor (VEGF) plays a pivotal role in the development of diabetic macular edema (DME), the leading cause of vision loss among working-aged individuals. A decade of clinical trials demonstrated that drugs that bind soluble VEGF restore the integrity of the blood-retinal barrier, resolve macular edema, and improve vision in most patients with DME. Four drugs (pegaptanib, ranibizumab, bevacizumab, and aflibercept) effectively treat DME when administered by intravitreal injections. Only ranibizumab has received U.S. Food and Drug Administration (FDA) approval for DME, but bevacizumab is commonly used off-label, and an FDA application for aflibercept is pending. Effective treatment requires repeated injections, although recent data suggest that the treatment burden diminishes after 1 year. Intravitreal therapy is generally safe, although the incidence of systemic thromboembolic events varies among trials.

Klein BE. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol. 2007;14:179–83.PubMedCrossRef

Pascolini D, Mariotti SP. Global estimates of visual impairment: 2010. Br J Ophthalmol. 2012;96:614–8.PubMedCrossRef

Cowie C, Rust K, Byrd-Holt D, et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population. Diabetes Care. 2006;29:1263–8.PubMedCrossRef

Lee LL, Yu AP, Cahill KE, et al. Direct and indirect costs among employees with diabetic retinopathy in the United States. Curr Med Res Opin. 2008;24:1549–59.PubMedCrossRef

International Diabetes Federation. IDF Diabetes Atlas, 6th edn. Brussels, Belgium: International Diabetes Federation, 2013. http://www.idf.org/diabetesatlas. Accessed May 6, 2014.

Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103(2):137–49.PubMedCrossRef

Saaddine JB, Honeycutt AA, Narayan KM, Zhang X, Klein R, Boyle JP. Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus: United States, 2005-2050. Arch Ophthalmol. 2008;126:1740–7.PubMedCrossRef

Saaddine JB, Caldwell B, Gregg EW, et al. Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002. Ann Intern Med. 2006;144:465–74.PubMedCrossRef

Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in U.S. adults? Diabetes Care. 2008;31:81–6.PubMedCrossRef

10.

Rema M, Premkumar S, Anitha B, Deepa R, Pradeepa R, Mohan V. Prevalence of diabetic retinopathy in urban India: the Chennai Urban Rural Epidemiology Study (CURES) eye study, I. Invest Ophthalmol Vis Sci. 2005;46:2328–33.PubMedCrossRef

11.

Raman R, Rani PK, Reddi Rachepalle S, et al. Prevalence of diabetic retinopathy in India: Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetics Study report 2. Ophthalmology. 2009;116:311–8.PubMedCrossRef

12.

Minassian DC, Owens DR, Reidy A. Prevalence of diabetic macular oedema and related health and social care resource use in England. Br J Ophthalmol. 2012;96:345–9.PubMedCrossRef

13.

Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.CrossRef

14.

Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type I diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342:381–9.CrossRef

15.

Early Treatment of Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. ETDRS report No. 4. Int Ophthalmol Clin 1987;27:265-272.

16.

Early Treatment of Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. ETDRS report No. 1. Arch Ophthalmol 1985;103:1644-1652.

17.

Nagy JA, Benjamin L, Zeng H, Dvorak AM, Dvorak HF. Vascular permeability, vascular hyperpermeability and angiogenesis. Angiogenesis. 2008;11:109–19.PubMedCentralPubMedCrossRef

18.

Bates DO, Curry FE. Vascular endothelial growth factor increases microvascular permeability via a Ca(2+)-dependent pathway. Am J Physiol. 1997;273:H687–94.PubMed

19.

Roberts WG, Palade GE. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci. 1995;108:2369–79.PubMed

20.

Garrido-Urbani S, Bradfield PF, Lee BP, Imhof BA. Vascular and epithelial junctions: a barrier for leucocyte migration. Biochem Soc Trans. 2008;36:203–11.PubMedCrossRef

21.

Ku DD, Zaleski JK, Liu S, Brock TA. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am J Physiol. 1993;265:H586–92.PubMed

22.

Derevjanik NL, Vinores SA, Xiao WH, et al. Quantitative assessment of the integrity of the blood-retinal barrier in rabbits and primates. Invest Ophthalmol Vis Sci. 2002;43:2462–7.PubMed

23.

Ozaki H, Hayashi H, Vinores SA, et al. Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. Exp Eye Res. 1997;64:505–17.PubMedCrossRef

24.

Ishida S, Usui T, Yamashiro K, et al. VEGF₁₆₄ is pro-inflammatory in the diabetic retina. Invest Ophthalmol Vis Sci. 2003;44:2155–62.PubMedCrossRef

25.

Ishida S, Usui T, Yamashiro K, et al. VEGF₁₆₄-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med. 2003;198:483–9.PubMedCentralPubMedCrossRef

26.

Dor Y, Porat R, Keshet E. Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis. Am J Physiol. 2001;280:C1367–74.

27.

Pierce EA, Avery RL, Foley ED, et al. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci U S A. 1995;92:905–9.PubMedCentralPubMedCrossRef

28.

Ben-Av P, Crofford LJ, Wilder RL, Hla T. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett. 1995;372:83–7.PubMedCrossRef

29.

Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999;13:9–22.PubMed

30.

Funk M, Schmidinger G, Maar N, et al. Angiogenic and inflammatory markers in the intraocular fluid of eyes with diabetic macular edema and influence of therapy with bevacizumab. Retina. 2010;30:1412–9.PubMedCrossRef

31.

Funatsu H, Yamashita H, Noma H, et al. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol. 2002;133:70–7.PubMedCrossRef

32.

Nguyen QD, Shah SM, Van Anden E, et al. Supplemental oxygen improves diabetic macular edema: a pilot study. Invest Ophthalmol Vis Sci. 2004;45:617–24.PubMedCrossRef

33.

Campochiaro PA. C99-PKC412-003 Study Group. Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. Invest Ophthalmol Vis Sci. 2004;45:922–31.PubMedCrossRef

34.

Ruckman J, Green LS, Beeson J, et al. 2’-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF-165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon7-encoded domain. J Biol Chem. 1998;273:20556–67.PubMedCrossRef

35.

Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15:171–85.PubMedCentralPubMedCrossRef

36.

Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006;26:859–70.PubMedCrossRef

37.

Presta LG, Chen H, O’Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57:4593–9.PubMed

38.

Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A. 2002;99:11393–8.PubMedCentralPubMedCrossRef

39.

Ho AC, Scott IU, Kim SJ, et al. Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema. Ophthalmology. 2012;119:2179–88.PubMedCrossRef

40.••

Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE Study. Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615–25. This phase III trial demonstrated that ranibizumab with or without laser photocoagulation significantly improves vision more than laser photocoagulation.PubMedCrossRef

41.

Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117:1064–77.PubMedCentralPubMedCrossRef

42.••

Diabetic Retinopathy Clinical Research Network. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011;118:609–14. This phase III trial demonstrated that ranibizumab with prompt or deferred laser photocoagulation improves vision more than that laser photocoagulation or intraocular triamcinolone with laser.PubMedCentralCrossRef

43.••

Nguyen QD, Brown DM, Marcus DM, et al. RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789–801. This phase III trial demonstrated that monthly administration of two doses of ranibizumab (0.3 mg and 0.5 mg) over 2 years produces superior vision and macular thinning compared to laser, and frequently improves the severity of the retinopathy.PubMedCrossRef

44.

Sultan MB, Zhou D, Loftus J, Dombi T, Ice KS for the Macugen 1013 Study Group. A phase 2/3, multi-center, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Ophthalmology. 2011;118:1107–18.PubMedCrossRef

45.

Regeneron Press Release: http://investor.regeneron.com/releasedetail.cfm?releaseid=782911. Accessed February 24, 2014.

46.

Cunningham Jr ET, Adamis AP, Altaweel M, et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology. 2005;112:1747–57.PubMedCrossRef

47.

Nguyen QD, Tatlipinar S, Shah SM, et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol. 2006;142:961–9.PubMedCrossRef

48.

Chun DW, Heier JS, Topping TM, Duker JS, Bankert JM. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant macular edema. Ophthalmology. 2006;113:1706–12.PubMedCrossRef

49.

Nguyen QD, Shah SM, Heier JS, et al. Primary end point (six months) results of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology. 2009;116:2175–81.PubMedCrossRef

50.

Nguyen QD, Shan SM, Khwaja AA, et al. Two-year outcomes of ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology. 2010;117:2146–51.PubMedCrossRef

51.

Do DV, Nguyen QD, Khwaja AA, et al. Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged treatment. JAMA Ophthalmol. 2013;131:139–45.PubMedCrossRef

52.

Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials. Ophthalmology. 2013;120:2013–22.PubMedCrossRef

53.

Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study). Diabetes Care. 2010;33:2399–405.PubMedCentralPubMedCrossRef

54.

Lang GE, Berta A, Eldem BM, et al. Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study. Ophthalmology. 2013;120:2004–12.PubMedCrossRef

55.

Schachat SP. A new approach to the management of diabetic macular edema [Editorial]. Ophthalmology. 2013;117:1059–60.CrossRef

56.

Diabetes Retinopathy Clinical Research Network, Aiello LP, Beck RW, Bressler NM, et al. Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema. Ophthalmology. 2011;118:e5–e14.PubMedCentralPubMedCrossRef

57.

Scott IU, Edwards AR, Beck RW, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology. 2007;114:1860–7.PubMedCrossRef

58.

Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology. 2010;117:1078–86.PubMedCrossRef

59.•

Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol. 2012;130:972–9. This 2-year trial demonstrated that bevacizumab is superior to laser photocoagulation.PubMedCrossRef

60.

Soheilian M, Ramezani A, Obudi A, et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology. 2009;116:1142–450.PubMedCrossRef

61.

Soheilian M, Garfami KH, Ramezani A, Yaseri M, Peyman GA. Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina. 2012;32:314–21.PubMedCrossRef

62.

Arevalo JF, Sanchez JG, Wu L, et al. Primary intravitreal bevacizumab for diffuse diabetic macular edema. The Pan-American Collaborative Retina Study Group at 24 months. Ophthalmology. 2009;116:1488–97.PubMedCrossRef

63.

Do DV, Nguyen QD, Shah SM, et al. An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema. Br J Ophthalmol. 2009;93:114–49.CrossRef

64.•

Do DV, Nguyen QD, Boyer D, et al. One-year outcomes of the DA VINCI study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology. 2012;119:1658–65. This 1-year trial demonstrated that monthly or bimonthly aflibercept is superior to laser photocoagulation. PubMedCrossRef

65.

Campochiaro PA, Chaana R, Berger B, et al. Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase 1/2 study. Am J Ophthalmol. 2013;155:697–704.PubMedCrossRef

66.

http://www.thepharmaletter.com/article/uk-s-nice-backs-use-of-novartis-lucentis-for-diabetic-macular-edema. Accessed February 25, 2014.

67.

Nepomuceno AB, Takaki E, de Almeida FP P, et al. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema. Am J Ophthalmol. 2013;156:502–10.PubMedCrossRef

68.

Ollendorf DA, Colby JA, Pearson SD. Comparative effectiveness of anti-VEGF agents for diabetic macular edema. Int J Technol Assess Health Care. 2013;29:392–401.PubMedCrossRef

69.

Comparative effectiveness study of intravitreal aflibercept, bevacizumab, and ranibizumab for DME (Protocol T). Available from URL:http//clinicaltrials.gov/ct2/show/NCT01627249?term = aflibercept for DME&rank = 3.

70.

Lanzetta P, van Nuys K, Tran I, et al. The economic burden of diabetic macular edema from a U.S. private payer perspective. Fort Lauderdale, FL, USA: Association for Research in Vision and Ophthalmology (ARVO), Poster A370, 2011.

71.

Mitchell P, Annemans L, Gallagher M, et al. Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial. Br J Ophthalmol. 2012;96:688–93.PubMedCentralPubMedCrossRef

72.

Stein JD, Newman-Casey PA, Kim DD, Nwanyanwu KH, Johnson MW, Hutton DW. Cost-effectiveness of various interventions for newly diagnosed diabetic macular edema. Ophthalmology. 2013;120:1835–42.PubMedCrossRef

Titel: Anti-VEGF Therapy for Diabetic Macular Edema
verfasst von: Michael W. Stewart
Publikationsdatum: 01.08.2014
Verlag: Springer US
Erschienen in: Current Diabetes Reports / Ausgabe 8/2014
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-014-0510-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2014

Autologous Islet Transplantation in Patients Requiring Pancreatectomy for Neoplasm

Novel Urinary Biomarkers in Early Diabetic Kidney Disease

Goal Setting: An Integral Component of Effective Diabetes Care

Genetics of Diabetic Retinopathy

Cystic Fibrosis Related Diabetes